StocksMedium•9 November 2026•
1 min read
NeurAxis Q3 Revenue Surges 150% Amid Expanded Insurance Coverage
Key Facts
1NeurAxis announced record third quarter 2026 financial results driven by a 150% year-over-year revenue growth.
NeurAxis announced record third quarter 2026 financial results, with revenue surging 150% year-over-year to $2.0 million. The company stated in a GlobeNewswire release that this growth was primarily driven by the commercialization of its neuromodulation therapies for chronic conditions, alongside a 92% increase in IB-Stim unit deliveries.
The company attributed the performance to the activation of its Category I CPT code in January 2026, which expanded insurance coverage and lifted gross margins by 330 basis points to 86.6%. Regarding market performance, NRXS closed at $6.24 on November 6, 2026, prior to the release of results that showed a net loss of $6.5 million impacted by non-recurring stock compensation charges.